Výsledky vyhledávání - "Erika Bågeman"

369 Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies

Autor: Jeffrey Yachnin, Gustav Ullenhag, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Lena Schultz, Erika Bågeman, Camilla Wennersten, Charlotte Russell

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody developed as a first in class tumor-localizing CTLA-4 antibody for improved efficacy and reduced toxicity. Methods The study (NCT03782467) is a first-in-human dose escal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de66d4c8b9990b189330b5a22c505a4
https://doi.org/10.1136/jitc-2020-sitc2020.0369

Zobrazit plný text záznamu

Abstract CT145: A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody

Autor: Gustav J. Ullenhag, Kristoffer Staal Rohrberg, Erika Bågeman, Charlotte A. Russell, Jeffrey Yachnin, Ana Carneiro, Dorte Nielsen, Anne Månsson Kvarnhammar, Camilla Wennersten

Publikováno v: Cancer Research. 80:CT145-CT145

ATOR-1015 is evaluated in this first-in-human phase 1 study for safety and tolerability, as well as pharmacokinetics, immunogenicity and clinical efficacy (NCT03782467). ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody developed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c21eb26f8c71a2df0a79f738b993f68
https://doi.org/10.1158/1538-7445.am2020-ct145

Zobrazit plný text záznamu

Abstract P5-11-17: Body image in women with breast cancer using a scalp cooling system to reduce chemotherapy induced alopecia

Autor: Anne Moore, Erika Bågeman, Susan A. Melin, P Klein, M. Melisko, Tessa Cigler, ES Ver Hoeve, Glen D. Park, Sara A. Hurvitz, HS Rugo

Publikováno v: Cancer Research. 77:P5-11

Background: Most women consider hair to be an important part of body image. Alopecia is an emotionally traumatic side effect for breast cancer patients undergoing adjuvant chemotherapy. The DigniCap™ Scalp Cooling System is the first scalp cooling

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4294baf9b8e39e4826bbfe340a7c78a9
https://doi.org/10.1158/1538-7445.sabcs16-p5-11-17

Zobrazit plný text záznamu

A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody

Autor: Anne Månsson Kvarnhammar, Jeffrey Yachnin, Lena Schultz, Charlotte A. Russell, Gustav J. Ullenhag, Kristoffer Staal Rohrberg, Erika Bågeman, Camilla Wennersten, Dorte Nielsen, Ana Carneiro

Publikováno v: Journal of Clinical Oncology. 38:3061-3061

3061 Background: ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody developed to be a next generation CTLA-4 antibody with enhanced immune activation and tumor-directed activity for improved efficacy and reduced toxicity. Methods:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::627b532e8f88002afc5cfb57162bda6c
https://doi.org/10.1200/jco.2020.38.15_suppl.3061

Zobrazit plný text záznamu

A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015

Autor: Anne Månsson Kvarnhammar, Erika Bågeman, Jeffrey Yachnin, Dorte Nielsen, Ana Carneiro, Anna Dahlman, Charlotte A. Russell, Gustav J. Ullenhag, Camilla Wennersten, Kristoffer Staal Rohrberg

Publikováno v: Journal of Clinical Oncology. 37:TPS2653-TPS2653

TPS2653 Background: ATOR-1015 is a human bispecific IgG1 antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and the tumor necrosis factor receptor superfamily member 4, OX40 (also known as CD134). Both in vitro and in vivo, ATOR-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf8c2b52aff27782be35be10a17bd6fe
https://doi.org/10.1200/jco.2019.37.15_suppl.tps2653

Zobrazit plný text záznamu

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

Autor: Helena Jernström, Carsten Rose, Christian Ingvar, Erika Bågeman, Per-Ebbe Jönsson

Publikováno v: British Journal of Cancer

BACKGROUND: CYP2C8/9 polymorphisms may influence breast cancer-free survival after diagnosis due to their role in the metabolism of tamoxifen, paclitaxel, and other chemotherapy. cytochrome P450 (CYP)2C8/9 metabolise arachidonic acid to epoxyeicosatr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17279658788903744bcb2b246f4852f8
https://doi.org/10.1038/sj.bjc.6605428

Zobrazit plný text záznamu

Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: A pilot study comparing pre- and post-operative levels

Autor: Helena Jernström, Carsten Rose, Thomas L. Klug, Erika Bågeman, Christian Ingvar

Publikováno v: Molecular Genetics and Metabolism. 89:381-389

Most, but not all, studies have found that women with a high urinary 2-hydroxyestrogen (2OHE) to 16 alpha-hydroxyestrone (16 alpha OHE1) ratio are at reduced risk for breast cancer and have a better prognosis. The aim was to identify factors associat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97dbffe815221b9129ddeb53845b83ce
https://doi.org/10.1016/j.ymgme.2006.08.005

Zobrazit plný text záznamu

Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families

Autor: T Sandberg, Åke Borg, Helena Jernström, Håkan Olsson, Erika Bågeman

Publikováno v: British Journal of Cancer

BRCA1/2 mutations predispose to early-onset breast cancer, especially after oral contraceptive (OC) use and pregnancy. However, the majority of breast cancers might be due to more prevalent low-penetrance genes, which may also modify the risk in BRCA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37401032c0239214ab539433388a8334
https://doi.org/10.1038/sj.bjc.6602389

Zobrazit plný text záznamu

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

Autor: Sara A. Hurvitz, Jules T. Mitchel, Elizabeth S. Ver Hoeve, Glen D. Park, P Klein, Anne Moore, Erika Bågeman, Laura J. Esserman, Hope S. Rugo, Susan A. Melin, Michelle E. Melisko, Tessa Cigler, Ralph B. D'Agostino

Publikováno v: JAMA, vol 317, iss 6

ImportanceChemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited.ObjectivesTo evaluate whether use of a scalp cooling syst

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21237f6996c2c36fe2a4269c54d9798f
https://doi.org/10.1001/jama.2016.21038

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání